Sponsor

Baxalta Innovations GmbH

Austria Industriestrasse 67, Donaustadt, 1221 Vienna, Austria

About the sponsor

Clinical research in cTTP focuses on ADAMTS13 replacement and the management of microvascular thrombosis linked to severe deficiency of this enzyme. The studies address both prophylactic treatment and on-demand therapy in patients with inherited thrombotic disease.

ADAMTS13 replacement therapy
Thrombotic microangiopathy
Bleeding and clotting balance

The sponsor’s work in this area is centered on haematology and inherited disorders of coagulation control.

About Specializations

Baxalta Innovations GmbH runs clinical trials in conditions such as Primary immunodeficiency syndrome, Thrombotic thrombocytopenic purpura, Von Willebrand's disease, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

3 clinical trials

Primary immunodeficiency syndrome

Not recruiting

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Baxalta Innovations GmbH

Contact Research Centre

Thrombotic thrombocytopenic purpura

Not recruiting

Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

InvestigationalNo placebo

Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Apadamtase Alfa
Sponsor:Baxalta Innovations GmbH

Contact Research Centre

Von Willebrand's disease

Not recruiting

Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

Registered drugNo placebo

Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Octocog Alfa
Sponsor:Baxalta Innovations GmbH

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →

About the sponsor

About Specializations

Ongoing trials

3 clinical trials

Primary immunodeficiency syndrome

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

Thrombotic thrombocytopenic purpura

Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Von Willebrand's disease

Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

Are you running a clinical trial?

Prefer not to search? Our Concierge searches the trials for you.